Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1998 17
1999 20
2000 31
2001 31
2002 51
2003 74
2004 81
2005 79
2006 103
2007 89
2008 72
2009 92
2010 84
2011 98
2012 100
2013 75
2014 81
2015 41
2016 60
2017 61
2018 51
2019 49
2020 36
Text availability
Article attribute
Article type
Publication date

Search Results

1,353 results
Results by year
Filters applied: . Clear all
Page 1
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Yatham LN, et al. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. Bipolar Disord. 2018. PMID: 29536616 Free PMC article.
First-line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. ...In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview o …
First-line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasido …
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Taylor DM, Cornelius V, Smith L, Young AH. Taylor DM, et al. Acta Psychiatr Scand. 2014 Dec;130(6):452-69. doi: 10.1111/acps.12343. Epub 2014 Oct 6. Acta Psychiatr Scand. 2014. PMID: 25283309 Review.
METHOD: We performed a multiple-treatments meta-analysis of randomised, double-blind, controlled comparisons of 4-16 weeks in adults in bipolar depression. ...Olanzapine + fluoxetine was also ranked the highest for response with lurasidone second, but olanzapine
METHOD: We performed a multiple-treatments meta-analysis of randomised, double-blind, controlled comparisons of 4-16 weeks in adults in b
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.
Kishi T, Ikuta T, Matsuda Y, Iwata N. Kishi T, et al. Neuropsychopharmacol Rep. 2019 Sep;39(3):256-259. doi: 10.1002/npr2.12070. Epub 2019 Jul 8. Neuropsychopharmacol Rep. 2019. PMID: 31283865 Free article. Clinical Trial.
OBJECTIVE: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. ...A large scale, long-term, head-to-head comparis …
OBJECTIVE: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and …
Acute and maintenance treatments for bipolar depression.
Ketter TA. Ketter TA. J Clin Psychiatry. 2014 Apr;75(4):e10. doi: 10.4088/JCP.13010tx2c. J Clin Psychiatry. 2014. PMID: 24813411 Free article. Review.
Patients with bipolar disorder are symptomatic about half of the time, experiencing depression more often than mania/hypomania. ...Providing an accurate and timely bipolar depression diagnosis is critical for the proper treatment of the patient. Some FDA-approved tr …
Patients with bipolar disorder are symptomatic about half of the time, experiencing depression more often than mania/hypomania. ...Pr …
Olanzapine/fluoxetine combination for bipolar depression.
Shelton RC. Shelton RC. Expert Rev Neurother. 2006 Jan;6(1):33-9. doi: 10.1586/14737175.6.1.33. Expert Rev Neurother. 2006. PMID: 16466309 Review.
A clinical trial tested the relative effectiveness of the combination of olanzapine and fluoxetine in bipolar type I depression, against olanzapine alone or placebo. ...Therefore, the olanzapine/fluoxetine combination represents a viable alternative fo …
A clinical trial tested the relative effectiveness of the combination of olanzapine and fluoxetine in bipolar type I depressio …
Olanzapine: in adolescents with schizophrenia or bipolar I disorder.
McCormack PL. McCormack PL. CNS Drugs. 2010 May;24(5):443-52. doi: 10.2165/11204430-000000000-00000. CNS Drugs. 2010. PMID: 20369908 Review.
Olanzapine is an atypical antipsychotic that, in addition to its use in adults, is now indicated for the treatment of schizophrenia, and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years. ...Oral olanzapine was general
Olanzapine is an atypical antipsychotic that, in addition to its use in adults, is now indicated for the treatment of schizophrenia,
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Mahajan V, Arora M, Tandon VR, Gillani Z, Praharaj SK. Mahajan V, et al. J Clin Psychopharmacol. 2019 Jul/Aug;39(4):305-311. doi: 10.1097/JCP.0000000000001064. J Clin Psychopharmacol. 2019. PMID: 31205195 Clinical Trial.
Asenapine, a newer atypical antipsychotic, has been found to be effective for the treatment of mania, with efficacy similar to olanzapine. ...RESULTS: There was a significant reduction in Young Mania Rating Scale and Clinical Global Impression-Bipolar scores over ti …
Asenapine, a newer atypical antipsychotic, has been found to be effective for the treatment of mania, with efficacy similar to olanzapine
[Olanzapine].
Nagai N, Watanabe K. Nagai N, et al. Nihon Rinsho. 2013 Apr;71(4):666-72. Nihon Rinsho. 2013. PMID: 23678597 Review. Japanese.
Olanzapine is one of the SGAs (second-generation antipsychotics) which have been used for the treatment of patients with schizophrenia and bipolar disorder in Japan. ...Therefore, olanzapine is known as MARTA(multi-acting receptor targeted antipsychotics). Nu
Olanzapine is one of the SGAs (second-generation antipsychotics) which have been used for the treatment of patients with schizophreni
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.
Cipriani A, Rendell J, Geddes JR. Cipriani A, et al. J Psychopharmacol. 2010 Dec;24(12):1729-38. doi: 10.1177/0269881109106900. Epub 2009 Oct 14. J Psychopharmacol. 2010. PMID: 19828571 Review.
Olanzapine was licensed in the USA by the Food and Drug Administration in 2003 for the prevention of relapse in patients with bipolar disorder when the acute manic episode had responded to treatment with olanzapine. However, olanzapine is commonly used
Olanzapine was licensed in the USA by the Food and Drug Administration in 2003 for the prevention of relapse in patients with bipo
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Cipriani A, et al. Cochrane Database Syst Rev. 2013 Oct 17;2013(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. Cochrane Database Syst Rev. 2013. PMID: 24132760 Free PMC article. Review.
BACKGROUND: Bipolar disorder is a recurrent illness that is amongst the top 30 causes of disability worldwide and is associated with significant healthcare costs. ...Two studies (overall 312 participants) compared valproate with placebo, four studies (overall 618 participa …
BACKGROUND: Bipolar disorder is a recurrent illness that is amongst the top 30 causes of disability worldwide and is associated with …
1,353 results
Jump to page
Feedback